+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Anti-Fungal Drugs Market - Growth, Trends and Forecast 2017 - 2022

  • ID: 4388602
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global Anti-Fungal drugs market accounted for a market value of USD XX million in 2015 and is expected to reach USD XX million by 2016. The market is expected to reach USD XX million by 2021, growing at a CAGR of X% during the forecast period of 2016 to 2021.

Anti fungal agent are drugs that detects and eliminates fungal pathogens from foreign body with minimal toxic side effects to the body. The anti-fungal agent market growth is increasing due to rise in number of patients suffering from hygiene related diseases in developing countries and some of the developed countries. The Global antifungal market is dominated by systemic antifungal infection. This market for systemic agents for serious infection is currently served by only three major drug classes, Azoles, Polyenes, Echinocandins and Allylamines. The global antifungal drugs market is expected to witness a lucrative growth during the forecast period owing to the increasing awareness about the myriad fungal infections, increasing government and corporate initiatives, rise in number of immune-compromised aged population, and rise in population that come in contact with resistant fungal strains and infections.

The market is restrained mainly because of growing resistance to antifungal drugs, presence of generics and government regulations in pharmaceutical industry and allergic reaction to some types of anti-fungal drugs.

The global antifungal drugs market can be segmented on the basis of type of drug, and therapeutic indication. Depending on the line of treatment, antifungal agents are divided into Azoles, Echinocandins, Polyenes, Allyamines and others. Of these the azole class consists of Voricanazole, Imidazole, Triazole and Thiazoles. Voriconazole is identified as the market leading agent. The Echinocandins are the latest class of agent to be introduced to the market but crude mortality remains high. Increasing resistance is being seen amongst Candida and Apsergillus species particularly to azoles and this is thought to be driven by the use of azoles in agriculture. Allylamines contain agents such as Lamisil and Terbinafine. Therapeutic indicators have been segmented into Dermatophytosis, Candidiasis, Aspergillosis and others.

This report have been geographically segmented into North America, Europe, Asia-Pacific, Middle East & Africa and South America. The North American region have been further segmented into USA, Canada and Mexico. The Europe region have been sub-divided into Germany, France, UK, Spain, Italy, Scandinavia, Benelux and Rest of Europe. The Asia-Pacific market have been segmented into Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East & African market have been subdivided into GCC countries, South Africa and rest of Middle East and Africa. The South American market have been segmented into Brazil, Argentina and rest of South America.

In 2014, North America accounted for the largest market share owing to increasing incidences of fungal infections and development of novel antifungal biopharmaceuticals. Emerging economies such as India and China in the Asia Pacific region are expected to grow at a significant rate in the next seven years. The myriad reasons for this trend include increasing awareness towards health care and personal care, increasing per capita income of the population and increasing transparency in the APAC region supply-chain. India’s tropical environment is a breeding ground for varied types of fungi and hence provides a lot of opportunities to the Pharma operators to keep the drug market flooded with various anti-fungal drugs.

The global antifungal drugs market is highly competitive owing to emergence of new entrants in the market and the presence of well established firms. Government reforms also play an elemental role in growing this market. The government employed various measures on its own including public private partnership (PPP) which have indeed helped pharma operators from anti-fungal drug category grow. The biggest problem that the current market needs to tackle is the growing resistance to Anti-fungal drugs

The key players in the market are Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland).

Key Deliverables:

Market analysis for the Global Anti-Fungal Drugs market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Global Anti-Fungal Drugs market

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Note: Product cover images may vary from those shown
2 of 3
1.1 Study deliveratives
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and forecast period years
1.6 General Study Assumptions
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
5.1 Current market scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of suppliers
5.2.2 Bargaining power of buyers
5.2.3 Degree of competition
5.2.4 Threat of substitution
5.2.5 Threat of new entrants
6.1 Market Drivers
6.1.1 Increasing awareness about the myriad fungal infections
6.1.2 Increasing government and corporate funding
6.1.3 Rise in number of immune-compromised aged population
6.1.4 Increasing population coming in contact with resistant fungal strains and infections
6.2 Market Restraints
6.2.1 High penetration of conventional drugs used for treatment
6.2.2 Presence of generics and government regulations in pharmaceutical industry
6.2.3 Allergic reaction to some types of anti-fungal drugs
6.3 Market opportunities
6.3.1 Introduction of New Anti-Fungal Drugs
6.4 Key Challenges
6.4.1 Increasing resistance to Anti-fungal drugs
7.1.1 Echinocandins Pneumocandins Caspofungin Micafungin Anidulafungin Others
7.1.2 Azoles Voricanazole Imidazoles Triazoles Thiazoles Others
7.1.3 Polyenes Amphotericin B Candicidin Hamycin Natamycin Others
7.1.4 Allylamines Lamisil Terbinafine Others
7.1.5 Others Benzoic Acid Ciclopirox Greisiofulvin
7.2.1 Aspergillosis
7.2.2 Dermatophytosis
7.2.3 Candidiasis
7.2.4 Others
8. Global Anti-fungal agents market by Geography - Regional shares and forecast
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Asperqillus
10.2 Alternaria
10.3 Abbott Laboratories
10.4 Pfizer
10.5 Glaxosmithkline
10.6 Bayer Healthcare
10.7 Novartis
10.8 Sanofi-Aventis
10.9 Merck & Co.
10.10 Kramer Laboratories
10.11 Enzon Pharmaceuticals
10.12 Gilead
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3